SAN

81.67

-0.97%↓

MRK1

119.65

-0.17%↓

SHL.DE

44.82

+1.11%↑

ARGX

725.4

-1.17%↓

FRE

48.51

+0.37%↑

SAN

81.67

-0.97%↓

MRK1

119.65

-0.17%↓

SHL.DE

44.82

+1.11%↑

ARGX

725.4

-1.17%↓

FRE

48.51

+0.37%↑

SAN

81.67

-0.97%↓

MRK1

119.65

-0.17%↓

SHL.DE

44.82

+1.11%↑

ARGX

725.4

-1.17%↓

FRE

48.51

+0.37%↑

SAN

81.67

-0.97%↓

MRK1

119.65

-0.17%↓

SHL.DE

44.82

+1.11%↑

ARGX

725.4

-1.17%↓

FRE

48.51

+0.37%↑

SAN

81.67

-0.97%↓

MRK1

119.65

-0.17%↓

SHL.DE

44.82

+1.11%↑

ARGX

725.4

-1.17%↓

FRE

48.51

+0.37%↑

Home・Akciju saraksts・Pharming Group NV

P
Pharming Group NV

Slēgts

1.455 4.45

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.387

Max

1.458

Galvenie mērījumi
By Trading Economics
Ienākumi	2.9M 7.5M
Pārdošana	4.1M 97M
EPS	0.009
Peļņas marža	7.758
Darbinieki	404

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	768K 998M
Iepriekšējā atvēršanas cena	-2.99
Iepriekšējā slēgšanas cena	1.455

Pharming Group NV Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 22. dec. 23:54 UTC

Galvenie tirgus virzītāji

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

2025. g. 22. dec. 19:08 UTC

Iegādes, apvienošanās, pārņemšana

Correction to Alphabet to Buy Intersect Article

2025. g. 22. dec. 17:21 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

2025. g. 22. dec. 16:46 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet to Buy Intersect for $4.75 Billion in Cash

2025. g. 22. dec. 23:50 UTC

Tirgus saruna

Nikkei May Decline as Yen Rebounds -- Market Talk

2025. g. 22. dec. 23:42 UTC

Tirgus saruna

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

2025. g. 22. dec. 22:31 UTC

Peļņas

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

2025. g. 22. dec. 22:31 UTC

Peļņas

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

2025. g. 22. dec. 22:30 UTC

Peļņas

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

2025. g. 22. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 22. dec. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 22. dec. 21:37 UTC

Iegādes, apvienošanās, pārņemšana

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

2025. g. 22. dec. 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

2025. g. 22. dec. 21:35 UTC

Iegādes, apvienošanās, pārņemšana

Capricorn to Acquire Prospective Package From Tempest Minerals

2025. g. 22. dec. 21:35 UTC

Iegādes, apvienošanās, pārņemšana

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

2025. g. 22. dec. 20:54 UTC

Iegādes, apvienošanās, pārņemšana

Middle West Partners Buys Paul Stuart From Mitsui & Co.

2025. g. 22. dec. 20:52 UTC

Iegādes, apvienošanās, pārņemšana

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

2025. g. 22. dec. 20:09 UTC

Tirgus saruna

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

2025. g. 22. dec. 19:56 UTC

Tirgus saruna

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

2025. g. 22. dec. 19:49 UTC

Iegādes, apvienošanās, pārņemšana

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

2025. g. 22. dec. 19:23 UTC

Tirgus saruna

Mexico's Inflation Seen Easing in Early December -- Market Talk

2025. g. 22. dec. 19:23 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 22. dec. 19:02 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 22. dec. 19:02 UTC

Tirgus saruna

Precious Metals Climb to New Heights -- Market Talk

2025. g. 22. dec. 18:45 UTC

Tirgus saruna

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

2025. g. 22. dec. 18:30 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

2025. g. 22. dec. 18:23 UTC

Iegādes, apvienošanās, pārņemšana

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

2025. g. 22. dec. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 22. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 22. dec. 17:06 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Salīdzinājums

Cenas izmaiņa

Pharming Group NV Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pharming Group NV — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.